Bivalirudin improves net clinical outcomes and increases survival in heart attack patients
Monday, May 26, 2008 - 12:35
in Health & Medicine
A study led by Gregg W. Stone, M.D., professor of medicine at Columbia University Medical Centre/NewYork-Presbyterian and chairman of the Cardiovascular Research Foundation, has shown that heart attack patients who were administered the direct thrombin inhibitor bivalirudin during primary angioplasty had a reduced rate of adverse clinical events...
Read the whole article on Science Centric
More from Science Centric
Related
- Findings released from 1 of the largest percutaneous coronary intervention trials everFri, 23 May 2008, 12:21:58 EDT
- Landmark study reveals superiority of bivalirudin in heart attack patients at 30 daysThu, 22 May 2008, 8:21:50 EDT
- Drug-eluting stents better than bare-metal stents for heart attack patientsFri, 25 Sep 2009, 15:35:45 EDT
- First heart patients implanted with next-generation mechanical heart pumpTue, 2 Jun 2009, 13:09:02 EDT
- NEJM study finds drug-eluting stents more effective than bare-metal stents in heart attack patientsTue, 26 May 2009, 14:43:06 EDT